---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-042652"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:12:41.913606+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11

## Summary
- Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).
- Med Device segment sales $39.5M (-3.6% YoY); U.S. Med Device grew 2.1%.
- GAAP net loss $12.8M ($0.31 loss/share); adjusted net loss $4.4M ($0.11 loss/share).
- Submitted NanoKnife PRESERVE study to FDA for 510(k) prostate tissue indication; received CE Mark for Auryon in Europe.
- FY2025 guidance reaffirmed: net sales $282-288M, adj. EBITDA loss $2.5M-$0, adj. EPS loss $0.38-$0.42.

## SEC filing metadata
- accession: 0001140361-24-042652
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036124042652/0001140361-24-042652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036124042652/ef20036580_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-042652
- JSON: https://secwatch.observer/filing/0001140361-24-042652.json
- Plain text: https://secwatch.observer/filing/0001140361-24-042652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.